抑郁症对TAVR等待时间和TAVR后结果的影响:基于人口的研究
Zahi Abu Ghosh1,2, Feng Qiu3, Ragavie Manoragavan1
1Schulich Heart Program, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, D-410, Toronto, Ontario M4N 3M5, Canada.
European heart journal open
|February 26, 2026
概括
预先存在的抑郁症影响了近三分之一的经过过导管大动脉置换 (TAVR) 的患者. 虽然抑郁症不会改变等待时间的结果,但它增加了TAVR后意外住院的风险.
科学领域:
- 心血管医学 心血管医学
- 精神病医学 精神病医学
- 医疗保健服务研究 医疗服务研究
背景情况:
- 越来越多的跨导管大动脉置换 (TAVR) 需求使医疗保健能力受到压力,导致延迟.
- 预先存在的抑郁症对TAVR患者结局的影响仍未得到充分研究.
研究的目的:
- 研究先前存在的抑郁症与转诊TAVR的患者的结局之间的关联.
- 分析抑郁症对TAVR前后等待时间,死亡率和住院病人的影响.
主要方法:
- 加拿大安大略省的一项基于人口的研究分析了12789个TAVR转诊病例 (2018年4月至2023年3月).
- 通过医疗保健数据库确定了抑郁症;从转诊到手术,死亡或退出列表的等待时间被测量.
- 多变量Cox比例危险模型评估了TAVR前后的结果,包括死亡率和意外住院.
主要成果:
- 31%的TAVR转诊者有先前存在的抑郁症;等待时间的中位数在各组之间是相似的 (75天与72天).
- 在TAVR等待期内,抑郁症与死亡率或住院无关.
- 在TAVR后,抑郁症与更高的无计划住院率有关 (HR 1.10,95% CI 1.03-1.17).
结论:
- 以前存在的抑郁症在TAVR候选人中很常见,但不会影响等候名单的结果.
- 抑郁症是TAVR后非计划性住院的独立风险因素,突出了针对性术后护理的需要.
相关概念视频
Long-term Depression
33.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
33.5K
Long-term Depression
3.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
3.5K
Depression: Overview
1.1K
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
1.1K
Depressive Disorders: Etiology
793
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
793
Depressive Disorders: MDD and Dysthymia
911
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
911
Therapeutic Drug Monitoring: Affecting Factors
288
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
288


